Galena Biopharma to Present GALE-302 Preliminary Immunological Data Optimizing GALE-301, and the Phase 2 NeuVax Data Impact on Cancer Survivorship at Two Upcoming Medical Conferences SAN RAMON, Calif., Oct. 22, 2015 -- Galena Biopharma, Inc. , a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that data from the Company's NeuVax and GALE-301 and GALE-302 clinical programs will be presented at two upcoming medical conferences.